摘要目的:探讨多发性骨髓瘤(multiple myeloma, MM)外周血中血清B细胞成熟抗原(serum B-cell maturation antigen, sBCMA)表达水平对MM患者疾病状态和疗效的评估作用。方法:收集2018年1月至2021年10月于中国人民解放军联勤保障部队第901医院43例初诊、16例复发和13例完全缓解MM患者以及40例健康志愿者外周血，采用酶联免疫吸附试验(enzyme linked immunosorbent assay，ELISA)检测血浆中sBCMA水平，并分析sBCMA与MM患者临床特征的相关性。结果:初诊MM患者外周血中sBCMA的表达水平相比对照组明显升高，差异具有统计学意义[ng/mL：(55.72±11.25)比(16.24±5.19) , t＝14.42, P<0.05]。sBCMA水平与初诊MM患者骨髓中浆细胞比例和M蛋白水平呈正相关( r值分别为0.56和0.64, P值均<0.05)。sBCMA与初诊MM患者的年龄、性别、M蛋白亚型、肾功能以及(international staging system，ISS)分期均未见明显相关性( P值均>0.05)。初诊MM患者经治疗后，sBCMA的表达水平显著下降[ng/mL：(57.34±12.05)比(23.26±11.76)， t＝12.34, P<0.05]。初诊和复发MM患者外周血中sBCMA表达水平较完全缓解组患者显著升高，差异具有统计学意义[ng/mL：(55.72±11.25)比(59.33±12.16)比(19.32±7.21)， F＝203.07, P<0.05]。初诊和复发组MM外周血中sBCMA表达水平差异无统计学意义( P>0.05)。 结论:sBCMA可能作为一种评估MM患者疾病状态以及疗效的新指标，通过靶向sBCMA的研究，可能有助于研发MM的治疗新方法。

abstractsObjective:To study the level of serum B-cell maturation antigen (sBCMA) in peripheral blood of multiple myeloma (MM) and its role in evaluating the disease status and efficacy of treatment.Methods:From January 2018 to October 2021, 43 newly diagnosed, 16 relapsed, 13 complete remission MM patients and 40 healthy volunteers were selected in the 901th Hospital of PLA. the levels of sBCMA in plasma were detected by enzyme linked immunosorbent assay (ELISA). The correlation between sBCMA and the clinical characteristics of MM patients was analysed.Results:The level of sBCMA in peripheral blood of newly diagnosed MM patients was significantly higher than that in the control group [ng/mL: (55.72±11.25) vs (16.24±5.19), t=14.42, P<0.05]. The level of sBCMA was positively correlated with the proportion of plasma cells and the level of M protein in newly diagnosed MM patients ( r values were 0.56 and 0.64, respectively, both P values <0.05). There was no significant correlation between sBCMA with the age, gender, M protein subtype, renal function and international staging system(ISS) stage of newly diagnosed MM patients (both P>0.05). After treatment, the level of sBCMA decreased significantly [ng/mL: (57.34±12.05) vs (23.26±11.76) , t=12.34, P<0.05]. The level of sBCMA in newly diagnosed and relapsed MM patients was significantly higher than that of patients in the complete remission group [ ng/mL: (55.72±11.25) vs (59.33±12.16)vs(19.32±7.21), F=203.07, P<0.05]. There was no significant difference in the level of sBCMA between the newly diagnosed and relapsed groups ( P>0.05). Conclusion:sBCMA may be used as a new indicator to evaluate the disease state and efficacy of treatment. Research targeting sBCMA may help to develop new treatment methods for MM.